Pfizer’s experimental obesity drug, acquired through Metsera, showed significant weight loss when taken once a month in a mid-stage trial. Patients lost up to 12.3% of their weight compared to the placebo at week 28, with no plateau observed after transitioning to monthly dosing. Pfizer plans to move forward with 10 phase three trials this year. Pfizer’s injection is an ultra-long-acting GLP-1 drug engineered for weekly and monthly dosing, offering a more convenient option for patients. Shares of Pfizer closed nearly 3% lower on Tuesday despite the positive results.

Read more at CNBC: Pfizer’s monthly obesity injection drove shows promise in trial